Propanc Biopharma, Inc.

Propanc Biopharma, Inc.

Core business

• Biopharmaceutical company developing a proenzyme therapy (PRP) intended to prevent recurrence and metastasis of solid tumors by targeting cancer stem cells.
• Lead candidate PRP combines pancreatic proenzymes trypsinogen and chymotrypsinogen, administered intravenously in a fixed synergistic ratio.
• Therapeutic approach centers on differentiation therapy to steer cancer cells toward less malignant phenotypes and reduce metastatic potential, with focus on cancer stem cells and the tumor microenvironment.

Lead product and development status

• PRP is in preclinical development with plans to progress to human studies.
• Regulatory and clinical plans:
  • Submit a Clinical Trial Application (CTA) in Australia in late 2026.
  • If the CTA is approved, initiate a Phase Ib (First-In-Human) study in advanced solid tumors in 2027, followed by Phase IIa studies, subject to capital and regulatory progress.
• Orphan Drug status:
  • FDA Orphan Drug Designation for pancreatic cancer granted in June 2017.
  • An orphan designation request for ovarian cancer in 2017 was not granted.

Intellectual property

• Broad patent portfolio covering proenzyme formulations for cancer treatment.
• As of June 30, 2026: 85 granted, allowed, or accepted patents and 4 patent applications filed or under examination in key jurisdictions related to PRP.
• Key collaboration-related IP and commercial terms:
  • University of Bath: commercialization agreement with royalty arrangement (2% of net revenues; plus 5% of each license acquired).
  • University of Jaén and University of Granada: collaboration agreements with royalties tied to net sales (various percentages); resulting industrial property rights belong to Propanc.
• Ongoing and planned collaborations to develop synthetic/proenzyme variants and backup compounds (POP1 program).

Market and strategy

• Target indications: solid tumors with emphasis on pancreatic and ovarian cancers, and potential exploration in other solid tumors and cancer prevention contexts.
• Market context: references to a large global metastatic cancer market (e.g., an estimate of $111 billion by 2027) and unmet need in pancreatic and ovarian cancers.
• Development strategy: advance early-stage clinical development to achieve proof-of-concept and efficacy milestones, then seek licensing partners for later-stage development and commercialization.

Operational status and commercial

• Commercial status: pre-revenue; product candidates remain in development.

People and facilities

• As of June 30, 2026, the company reported two full-time employees.
• Principal office: Camberwell, Victoria, Australia.
• Property arrangements include leases with related parties (North Horizon Pty Ltd. and Horizon Pty Ltd.).

Regulatory and compliance

• Regulatory considerations described include the standard development pathway (IND/CTA, Phase I–IV), GMP expectations, and post-approval obligations.
• Australia R&D incentives: potential cash-back up to 43.5% on eligible R&D expenses; the company reported $0 refunds for 2026 and 2025 under this incentive.

Financial notes of interest

• IRS liability: penalty for late Form 5471 filings related to a foreign subsidiary. Total penalty recorded was $30,000 plus accrued interest; the company is current on subsequent filings.
• The company emphasizes its pre-revenue status and the need for additional capital to fund clinical development and working capital.

Summary

Propanc Biopharma is developing PRP, a pancreatic proenzyme-based therapy aimed at preventing recurrence and metastasis of solid tumors by inducing cancer cell differentiation and targeting cancer stem cells. PRP is in preclinical development with a planned CTA submission in Australia in late 2026 and a potential Phase Ib study in 2027, subject to regulatory approval and financing. The company maintains an expanding IP portfolio, collaborates with academic partners under royalty arrangements, and is positioned to pursue early clinical milestones before seeking licensing or partnership opportunities.